Patrick Jean‐Philippe
Biographic Data
| ID | 9116291 |
|---|---|
| NAME | Patrick Jean‐Philippe |
| GIVEN NAMES | Patrick |
| FAMILY NAME | Jean‐Philippe |
| SIGNATURE | PHILIPPE P J |
| AFFILIATIONS | National Institutes of Health |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2008 |
| LATEST PUBLICATION YEAR | 2013 |
| H-INDEX | 0 |
Ethical Tradeoffs in Trial Design
The D eclaration of H elsinki and the C ouncil of the I nternational O rganization of M edical S ciences provide guidance on standards of care and prevention in clinical trials. In the current and increasingly challenging research environment, the ethical status of a trial design depends not only on protection of participants, but also on social value, feasibility, and scientific validity. Using the example of a study assessing efficacy of a vacc…
Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
BACKGROUND: In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial. METHODS: HIV-infected infants 6 to 12 weeks of age with a CD4 lymphocyte percentage (the CD4 percentage) of 25% or more were randomly assigned to receive antiretroviral …
No prominent works on this page.
Early Antiretroviral Therapy and Mortality among HIV-Infected Infants
BACKGROUND: In countries with a high seroprevalence of human immunodeficiency virus type 1 (HIV-1), HIV infection contributes significantly to infant mortality. We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial. METHODS: HIV-infected infants 6 to 12 weeks of age with a CD4 lymphocyte percentage (the CD4 percentage) of 25% or more were randomly assigned to receive antiretroviral …
Ethical Tradeoffs in Trial Design
The D eclaration of H elsinki and the C ouncil of the I nternational O rganization of M edical S ciences provide guidance on standards of care and prevention in clinical trials. In the current and increasingly challenging research environment, the ethical status of a trial design depends not only on protection of participants, but also on social value, feasibility, and scientific validity. Using the example of a study assessing efficacy of a vacc…
Medicine (2 works) · Antibody (1 work) · ANTIRETROVIRAL AGENTS (1 work) · Antiretroviral therapy (1 work) · Antiretroviral treatment (1 work) · Clinical trial (1 work) · Hepatitis B Virus Studies (1 work) · HIV-related health complications and treatments (1 work) · HIV/AIDS drug development and treatment (1 work) · HIV/AIDS Research and Interventions (1 work)